MC-SN38 is primarily used in the field of cancer research and treatment. It is a prodrug of SN-38, which is the active metabolite of the chemotherapy drug irinotecan. MC-SN38 is designed to improve the delivery and efficacy of SN-38 by enhancing its solubility and stability, thereby reducing side effects and increasing its therapeutic potential. This compound is particularly investigated for its application in targeted cancer therapies, where it can be conjugated to antibodies or nanoparticles to specifically deliver the cytotoxic agent to tumor cells. Its use is being explored in various cancers, including colorectal, pancreatic, and breast cancer, to improve treatment outcomes and minimize damage to healthy tissues.